XML 23 R39.htm IDEA: XBRL DOCUMENT v3.20.1
Share-based Compensation (Tables)
9 Months Ended
Mar. 31, 2020
Share-based Compensation  
Schedule of weighted average assumptions

 

 

 

 

 

 

 

 

 

 

Nine Months Ended

    

 

 

March 31, 2020

 

March 31, 2019

 

Risk-free interest rate

 

 

1.9

%

 

2.9

%

Expected volatility

 

 

73.7

%

 

58.4

%

Expected dividend yield

 

 

 —

%

 

 —

%

Forfeiture rate

 

 

 —

%

 

6.5

%

Expected term

 

 

5.1

years

 

5.3

years

Weighted average fair value

 

$

4.04

 

$

6.52

 

 

Summary of stock option award activity

 

 

 

 

 

 

 

 

 

 

 

 

    

    

    

 

 

    

 

 

    

Weighted

 

 

 

 

Weighted-

 

 

 

 

Average

 

 

 

 

Average

 

Aggregate

 

Remaining

 

 

 

 

Exercise

 

Intrinsic

 

Contractual

(In thousands, except for weighted average price and life data)

    

Awards

    

Price

    

Value

    

Life (yrs.)

Outstanding at June 30, 2019

 

572

 

17.56

 

$

273

 

5.0

Granted

 

522

 

6.57

 

 

 

 

 

Exercised

 

(50)

 

5.60

 

$

210

 

 

Forfeited, expired or repurchased

 

(34)

 

24.89

 

 

 

 

 

Outstanding at March 31, 2020

 

1,010

 

12.22

 

$

503

 

5.8

 

 

 

 

 

 

 

 

 

 

 

Vested and expected to vest at March 31, 2020

 

1,008

 

12.21

 

$

503

 

5.8

Exercisable at March 31, 2020

 

513

 

16.85

 

$

334

 

2.6

 

Summary of non-vested restricted stock awards

 

 

 

 

 

 

 

 

 

 

 

 

 

Weighted

 

 

 

 

 

 

 

Average Grant -

 

Aggregate

(In thousands, except for weighted average price data)

    

Awards

    

date Fair Value

    

Intrinsic Value

Non-vested at June 30, 2019

 

1,288

 

$

11.63

 

 

 

Granted

 

941

 

 

6.45

 

 

 

Vested

 

(751)

 

 

10.47

 

$

6,231

Forfeited

 

(70)

 

 

12.50

 

 

 

Non-vested at March 31, 2020

 

1,408

 

$

8.75

 

 

 

 

Schedule of non-vested performance-based shares

 

 

 

 

 

 

 

 

 

 

 

 

 

Weighted

 

 

 

 

 

 

 

Average Grant -

 

Aggregate

(In thousands, except for weighted average price and life data)

    

Awards

    

date Fair Value

    

Intrinsic Value

Non-vested at June 30, 2019

 

72

 

$

19.92

 

 

  

Granted

 

178

 

$

10.71

 

 

  

Vested

 

(46)

 

$

15.08

 

$

477

Forfeited

 

 —

 

$

 —

 

 

  

Non-vested at March 31, 2020

 

204

 

$

12.99

 

 

  

 

Schedule of allocation of share-based compensation

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Three Months Ended

 

Nine Months Ended

 

 

 

March 31, 

 

March 31, 

 

(In thousands)

    

2020

    

2019

    

2020

    

2019

 

Selling, general and administrative expenses

 

$

1,124

 

$

1,125

 

$

5,965

 

$

4,434

 

Research and development expenses

 

 

180

 

 

208

 

 

618

 

 

608

 

Cost of sales

 

 

566

 

 

656

 

 

1,753

 

 

1,932

 

Total

 

$

1,870

 

$

1,989

 

$

8,336

 

$

6,974

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Tax benefit at statutory rate

 

$

421

 

$

447

 

$

1,876

 

$

1,569